PROCESSA PHARMACEUTICALS INC (PCSA) Fundamental Analysis & Valuation

NASDAQ:PCSA • US74275C4033

Current stock price

3.02 USD
+0.15 (+5.23%)
At close:
2.94 USD
-0.08 (-2.65%)
After Hours:

This PCSA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PCSA Profitability Analysis

1.1 Basic Checks

  • PCSA had negative earnings in the past year.
  • In the past year PCSA has reported a negative cash flow from operations.
  • PCSA had negative earnings in each of the past 5 years.
  • In the past 5 years PCSA always reported negative operating cash flow.
PCSA Yearly Net Income VS EBIT VS OCF VS FCFPCSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • PCSA has a worse Return On Assets (-173.59%) than 85.42% of its industry peers.
  • PCSA has a worse Return On Equity (-243.20%) than 76.56% of its industry peers.
Industry RankSector Rank
ROA -173.59%
ROE -243.2%
ROIC N/A
ROA(3y)-244.24%
ROA(5y)-218.81%
ROE(3y)-388.25%
ROE(5y)-315.33%
ROIC(3y)N/A
ROIC(5y)N/A
PCSA Yearly ROA, ROE, ROICPCSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PCSA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCSA Yearly Profit, Operating, Gross MarginsPCSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. PCSA Health Analysis

2.1 Basic Checks

  • PCSA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for PCSA has been increased compared to 5 years ago.
  • There is no outstanding debt for PCSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PCSA Yearly Shares OutstandingPCSA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M 2.5M
PCSA Yearly Total Debt VS Total AssetsPCSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M

2.2 Solvency

  • Based on the Altman-Z score of -21.69, we must say that PCSA is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -21.69, PCSA is not doing good in the industry: 84.38% of the companies in the same industry are doing better.
  • PCSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -21.69
ROIC/WACCN/A
WACCN/A
PCSA Yearly LT Debt VS Equity VS FCFPCSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M

2.3 Liquidity

  • PCSA has a Current Ratio of 2.54. This indicates that PCSA is financially healthy and has no problem in meeting its short term obligations.
  • PCSA's Current ratio of 2.54 is in line compared to the rest of the industry. PCSA outperforms 45.83% of its industry peers.
  • A Quick Ratio of 2.54 indicates that PCSA has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.54, PCSA is in line with its industry, outperforming 52.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 2.54
PCSA Yearly Current Assets VS Current LiabilitesPCSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. PCSA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 81.42% over the past year.
EPS 1Y (TTM)81.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 39.75% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y78.83%
EPS Next 2Y30.52%
EPS Next 3Y39.44%
EPS Next 5Y39.75%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCSA Yearly Revenue VS EstimatesPCSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2027 2M 4M 6M
PCSA Yearly EPS VS EstimatesPCSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -200 -400 -600

More info and screens

Find the best growth stocksShow best growing peers

1

4. PCSA Valuation Analysis

4.1 Price/Earnings Ratio

  • PCSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year PCSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCSA Price Earnings VS Forward Price EarningsPCSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCSA Per share dataPCSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PCSA's earnings are expected to grow with 39.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.52%
EPS Next 3Y39.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PCSA Dividend Analysis

5.1 Amount

  • No dividends for PCSA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PCSA Fundamentals: All Metrics, Ratios and Statistics

PROCESSA PHARMACEUTICALS INC

NASDAQ:PCSA (4/8/2026, 8:00:00 PM)

After market: 2.94 -0.08 (-2.65%)

3.02

+0.15 (+5.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-18
Earnings (Next)05-06
Inst Owners5.08%
Inst Owner Change0%
Ins Owners0.84%
Ins Owner Change1.97%
Market Cap6.86M
Revenue(TTM)N/A
Net Income(TTM)-13.56M
Analysts82.86
Price Target25.5 (744.37%)
Short Float %2.05%
Short Ratio0.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-26.88%
Min EPS beat(2)-67.97%
Max EPS beat(2)14.22%
EPS beat(4)2
Avg EPS beat(4)0.37%
Min EPS beat(4)-67.97%
Max EPS beat(4)61.8%
EPS beat(8)4
Avg EPS beat(8)3.55%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)23.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.23
P/tB 1.23
EV/EBITDA N/A
EPS(TTM)-18.07
EYN/A
EPS(NY)-3.82
Fwd EYN/A
FCF(TTM)-5.02
FCFYN/A
OCF(TTM)-5.02
OCFYN/A
SpS0
BVpS2.46
TBVpS2.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -173.59%
ROE -243.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-244.24%
ROA(5y)-218.81%
ROE(3y)-388.25%
ROE(5y)-315.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 2.54
Altman-Z -21.69
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.11%
EPS Next Y78.83%
EPS Next 2Y30.52%
EPS Next 3Y39.44%
EPS Next 5Y39.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.25%
OCF growth 3YN/A
OCF growth 5YN/A

PROCESSA PHARMACEUTICALS INC / PCSA Fundamental Analysis FAQ

What is the fundamental rating for PCSA stock?

ChartMill assigns a fundamental rating of 2 / 10 to PCSA.


What is the valuation status of PROCESSA PHARMACEUTICALS INC (PCSA) stock?

ChartMill assigns a valuation rating of 1 / 10 to PROCESSA PHARMACEUTICALS INC (PCSA). This can be considered as Overvalued.


What is the profitability of PCSA stock?

PROCESSA PHARMACEUTICALS INC (PCSA) has a profitability rating of 0 / 10.